Table 3.

Immune responses (ELISPOT)

PatientSampleFlu peptidePSA3 peptide
1*Pre1/23,077<1/200,000
Post 31/21,429<1/200,000
Post 81/21,429<1/200,000
2*,Pre1/14,286<1/200,000
Post 31/8,9551/26,087
Post 81/13,3631/50,000
3*,Pre1/100,000<1/200,000
Post 31/150,0001/50,000
Post 81/150,0001/46,154
4,Pre1/42,8571/50,000
Post 31/46,1541/37,500
Post 81/46,1541/15,789
5§Pre1/31,579<1/200,000
Post 31/20,6901/46,154
Post 81/15,3851/30,000
6*,Pre1/21,4291/200,000
Post 31/20,0001/54,545
Post 81/13,0431/22,222
7§Pre1/18,182<1/200,000
Post 31/27,2731/42,857
Post 81/11,7651/15,000
8*,Pre1/17,647<1/200,000
Post 31/31,579<1/200,000
Post 81/28,5711/66,667
9*,,Pre1/7,692<1/200,000
Post 31/31,579<1/200,000
Post 81/9,836<1/200,000
10*,Pre1/26,0871/85,714
Post 31/11,1111/54,545
Post 81/15,3851/100,000
11Pre1/75,0001/100,000
Post 31/60,0001/85,714
Post 81/100,000<1/200,000
12*,Pre1/46,1541/100,000
Post 31/37,5001/150,000
Post 81/35,2941/200,000
13*,Pre1/60,0001/150,000
Post 31/60,0001/37,500
Post 81/60,0001/200,000
14*Pre1/15,789<1/200,000
Post 31/21,4291/28,571
Post 81/27,273<1/200,000
15,Pre1/30,000<1/200,000
Post 31/33,3331/66,667
Post 81/31,5791/20,000
16§Pre1/66,6671/100,000
Post 31/66,6671/15,789
Post 81/54,5451/75,000
17,Pre1/2,913<1/200,000
Post 31/3,1751/31,579
Post 81/4,4441/200,000
  • * Concomitant ADT started >1 month before vaccination.

  • Whole pelvic radiation.

  • Concomitant ADT started within 1 month before vaccination.

  • § No ADT.

  • Patient 9 had a postvaccine 5 PSA-specific precursor frequency of 1/24,000.